Zhuang Feng Zhuang Feng is in China.

Zhuang Xinfeng Pill (Shanghai) Chemical Co., Ltd. was established in Songjiang, Shanghai on July 6, 2000. Production started in June of 200 1 year. Now it covers an area of 24,000 square meters with a total investment of15 million USD. In June 2002, it was certified by QS9000 and VDA6. 1, and in May 2004.

At present, the company's products cover cars, light gasoline and diesel vehicle exhaust purification catalysts and motorcycle exhaust purification catalysts.

Since 1974 produced the catalyst for controlling automobile exhaust pollution, Zhuang Xinfeng pill has provided 1/3 of global automobile catalysts. Zhuang Xinfeng Pill has 16 production bases in Europe, North America, South America, Far East and Africa, and 9 technical centers provide professional technical solutions. About one third of the catalyst products we produce are used in automobiles. It can solve all kinds of automobile emission problems-whether it is nitrogen oxides, hydrocarbons, carbon monoxide emitted by gasoline-fueled vehicles that you are familiar with, or nitrogen oxide particles emitted by diesel vehicles-it can be easily solved.

20 1 1, Zhuang Xinfeng pill China technology center will be officially put into operation. Committed to providing more local automobile suppliers with comprehensive exhaust aftertreatment technology solutions and services. Zhuang Xinfeng Maruyakeelung (Shanghai) Environmental Protection Technology Co., Ltd. was established in Songjiang, Shanghai in 2008. Production started in September of 20 10. Now it covers an area of 20,000 square meters with a total investment of 90 million US dollars. Hebei Aoxing teamed up with famous British pharmaceutical companies to "build" the largest anesthesia base. Hebei Aoxing Group Pharmaceutical Co., Ltd. and Zhuang Xinfeng Pill Macfarlane Co., Ltd., a fortune 500 company, jointly established Hebei Aoxing Raw Material Medicine Co., Ltd., which will become the largest anesthetic manufacturer in China after the joint venture.

The reporter learned from the signing ceremony that the two companies will jointly develop and produce raw materials of naloxone and apply to develop raw materials of narcotic drugs in Xinle Industrial Park, China. It is estimated that the annual sales revenue will reach $654.38+0 billion, and the profit and tax will be $40 million. 30% of the products produced are exported.